{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:52:49Z","timestamp":1791075169383,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07971-7","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:22:36Z","timestamp":1790925756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allopurinol for Marfan Aortopathy: Pharmacogenomic Safety and Sex-Stratified Trial Design Warrant Consideration"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4057-1485","authenticated-orcid":false,"given":"Tahir","family":"Ullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Tariq","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"7971_CR1","doi-asserted-by":"publisher","unstructured":"Egea G, de Souza RB, Teixid\u00f3-Tur\u00e0 G, Mas-Stachurska A, Evangelista A, Loeys B. Introducing allopurinol to the medical treatment of marfan syndrome: advantages, limitations, and potential extension to other aortopathies. Cardiovasc Drugs Ther. 2026. https:\/\/doi.org\/10.1007\/s10557-026-07954-8.","DOI":"10.1007\/s10557-026-07954-8"},{"issue":"5","key":"7971_CR2","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1093\/ajhp\/zxae294","volume":"82","author":"HM Chua","year":"2025","unstructured":"Chua HM, Limenta M, Ng CYL, Lo EAG. Implementation of HLA-related genotype-guided prescribing in Singapore. Am J Health Syst Pharm. 2025;82(5):e285\u201393. https:\/\/doi.org\/10.1093\/ajhp\/zxae294.","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"7971_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/acr.80016","volume":"78","author":"A Fadairo-Azinge","year":"2026","unstructured":"Fadairo-Azinge A, Schmajuk G, Sharma S, et al. Effect of Implementing a Dashboard With or Without a Best Practice Alert on HLA-B*58:01 Testing Rates Among Allopurinol Users at VA Medical Centers. Arthritis Care Res (Hoboken). 2026;78(9):1265\u20139. https:\/\/doi.org\/10.1002\/acr.80016.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7971_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10557-023-07474-9","volume":"38","author":"A Sayed","year":"2024","unstructured":"Sayed A, Shazly O, Slipczuk L, et al. The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. Cardiovasc Drugs Ther. 2024;38:1415\u201320. https:\/\/doi.org\/10.1007\/s10557-023-07474-9.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"13","key":"7971_CR5","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cells15131225","volume":"15","author":"P Hunt","year":"2026","unstructured":"Hunt P, Huynh K, Gusek B, Stimpson A, Rahimian R, Esfandiarei M. Sex-Dependent Vascular Responses to Atorvastatin Across Multiple Arterial Beds in a Mouse Model of Marfan Syndrome. Cells. 2026;15(13):1225. https:\/\/doi.org\/10.3390\/cells15131225. Published 2026 Jul 7.","journal-title":"Cells"},{"key":"7971_CR6","doi-asserted-by":"publisher","first-page":"106554","DOI":"10.1016\/j.ejim.2025.106554","volume":"142","author":"C Borghi","year":"2025","unstructured":"Borghi C, Fogacci F, Cicero AF. Crystal clear - Part II: the role of uric acid in cardiorenal disease. Eur J Intern Med. 2025;142:106554. https:\/\/doi.org\/10.1016\/j.ejim.2025.106554.","journal-title":"Eur J Intern Med"},{"key":"7971_CR7","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10557-026-07866-7","volume":"40","author":"C Hou","year":"2026","unstructured":"Hou C, Zheng Z, Zheng X, et al. The Nonlinear Relationship Between Serum Uric Acid and Cardiovascular Disease Risk: Mechanistic Insights and Clinical Implications. Cardiovasc Drugs Ther. 2026;40:1917\u201326. https:\/\/doi.org\/10.1007\/s10557-026-07866-7.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7971_CR8","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s10557-026-07859-6","volume":"40","author":"Z Cao","year":"2026","unstructured":"Cao Z, Ma W, Liu C. Hyperuricemia and Hypoxic Pulmonary Hypertension: Pathogenic Links, Clinical Evidence, and Emerging Therapeutic Insights. Cardiovasc Drugs Ther. 2026;40:1881\u201397. https:\/\/doi.org\/10.1007\/s10557-026-07859-6.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07971-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:03:58Z","timestamp":1791072238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07971-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":8,"alternative-id":["7971"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07971-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"20 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Grammarly tool was used solely for the grammatical purposes like spelling, punctuation and other grammatical errors. All the scientific material and other ideas within the manuscript are belongs to the authors and are fully responsible for the originality of the manuscript.","order":1,"name":"Ethics","label":"Generative AI use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}